127 related articles for article (PubMed ID: 38546612)
1. Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
Fernandez-Martinez A; Rediti M; Tang G; Pascual T; Hoadley KA; Venet D; Rashid NU; Spears PA; Islam MN; El-Abed S; Bliss J; Lambertini M; Di Cosimo S; Huobe J; Goerlitz D; Hu R; Lucas PC; Swain SM; Sotiriou C; Perou CM; Carey LA
JAMA Oncol; 2024 May; 10(5):603-611. PubMed ID: 38546612
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials.
Fernandez-Martinez A; Pascual T; Singh B; Nuciforo P; Rashid NU; Ballman KV; Campbell JD; Hoadley KA; Spears PA; Pare L; Brasó-Maristany F; Chic N; Krop I; Partridge A; Cortés J; Llombart-Cussac A; Prat A; Perou CM; Carey LA
JAMA Oncol; 2023 Apr; 9(4):490-499. PubMed ID: 36602784
[TBL] [Abstract][Full Text] [Related]
3. Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer.
Zagami P; Fernandez-Martinez A; Rashid NU; Hoadley KA; Spears PA; Curigliano G; Perou CM; Carey LA
JAMA Netw Open; 2023 Dec; 6(12):e2348814. PubMed ID: 38117494
[TBL] [Abstract][Full Text] [Related]
4. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
[TBL] [Abstract][Full Text] [Related]
5. HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade.
Prat A; Pascual T; De Angelis C; Gutierrez C; Llombart-Cussac A; Wang T; Cortés J; Rexer B; Paré L; Forero A; Wolff AC; Morales S; Adamo B; Brasó-Maristany F; Vidal M; Veeraraghavan J; Krop I; Galván P; Pavlick AC; Bermejo B; Izquierdo M; Rodrik-Outmezguine V; Reis-Filho JS; Hilsenbeck SG; Oliveira M; Dieci MV; Griguolo G; Fasani R; Nuciforo P; Parker JS; Conte P; Schiff R; Guarneri V; Osborne CK; Rimawi MF
J Natl Cancer Inst; 2020 Jan; 112(1):46-54. PubMed ID: 31037288
[TBL] [Abstract][Full Text] [Related]
6. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
Carey LA; Berry DA; Cirrincione CT; Barry WT; Pitcher BN; Harris LN; Ollila DW; Krop IE; Henry NL; Weckstein DJ; Anders CK; Singh B; Hoadley KA; Iglesia M; Cheang MC; Perou CM; Winer EP; Hudis CA
J Clin Oncol; 2016 Feb; 34(6):542-9. PubMed ID: 26527775
[TBL] [Abstract][Full Text] [Related]
7. Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.
Fernandez-Martinez A; Krop IE; Hillman DW; Polley MY; Parker JS; Huebner L; Hoadley KA; Shepherd J; Tolaney S; Henry NL; Dang C; Harris L; Berry D; Hahn O; Hudis C; Winer E; Partridge A; Perou CM; Carey LA
J Clin Oncol; 2020 Dec; 38(35):4184-4193. PubMed ID: 33095682
[TBL] [Abstract][Full Text] [Related]
8. Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination.
Swain SM; Tang G; Lucas PC; Robidoux A; Goerlitz D; Harris BT; Bandos H; Geyer CE; Rastogi P; Mamounas EP; Wolmark N
Breast Cancer Res Treat; 2019 Nov; 178(2):389-399. PubMed ID: 31428908
[TBL] [Abstract][Full Text] [Related]
9. Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials.
Guarneri V; Griguolo G; Miglietta F; Conte PF; Dieci MV; Girardi F
ESMO Open; 2022 Apr; 7(2):100433. PubMed ID: 35276440
[TBL] [Abstract][Full Text] [Related]
10. Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial.
Powles RL; Redmond D; Sotiriou C; Loi S; Fumagalli D; Nuciforo P; Harbeck N; de Azambuja E; Sarp S; Di Cosimo S; Huober J; Baselga J; Piccart-Gebhart M; Elemento O; Pusztai L; Hatzis C
JAMA Oncol; 2018 Nov; 4(11):e181564. PubMed ID: 29902299
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
[TBL] [Abstract][Full Text] [Related]
12. Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer.
Huober J; Holmes E; Baselga J; de Azambuja E; Untch M; Fumagalli D; Sarp S; Lang I; Smith I; Boyle F; Xu B; Lecocq C; Wildiers H; Jouannaud C; Hackman J; Dasappa L; Ciruelos E; Toral Pena JC; Adamchuk H; Hickish T; de la Pena L; Jackisch C; Gelber RD; Piccart-Gebhart M; Di Cosimo S
Eur J Cancer; 2019 Sep; 118():169-177. PubMed ID: 31377477
[TBL] [Abstract][Full Text] [Related]
13. Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial.
Di Cosimo S; Appierto V; Pizzamiglio S; Tiberio P; Iorio MV; Hilbers F; de Azambuja E; de la Peña L; Izquierdo M; Huober J; Baselga J; Piccart M; de Braud FG; Apolone G; Verderio P; Daidone MG
Clin Cancer Res; 2019 Jul; 25(13):3887-3895. PubMed ID: 30814109
[TBL] [Abstract][Full Text] [Related]
14. Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.
Tanioka M; Fan C; Parker JS; Hoadley KA; Hu Z; Li Y; Hyslop TM; Pitcher BN; Soloway MG; Spears PA; Henry LN; Tolaney S; Dang CT; Krop IE; Harris LN; Berry DA; Mardis ER; Winer EP; Hudis CA; Carey LA; Perou CM
Clin Cancer Res; 2018 Nov; 24(21):5292-5304. PubMed ID: 30037817
[No Abstract] [Full Text] [Related]
15. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
[TBL] [Abstract][Full Text] [Related]
16. NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response.
Swain SM; Tang G; Brauer HA; Goerlitz DS; Lucas PC; Robidoux A; Harris BT; Bandos H; Ren Y; Geyer CE; Rastogi P; Mamounas EP; Wolmark N
Clin Cancer Res; 2020 Aug; 26(16):4233-4241. PubMed ID: 32371537
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial.
Gluz O; Nitz UA; Christgen M; Kuemmel S; Holtschmidt J; Schumacher J; Hartkopf A; Potenberg J; Lüedtke-Heckenkamp K; Just M; Schem C; von Schumann R; Kolberg-Liedtke C; Eulenburg CZ; Schinköthe T; Graeser M; Wuerstlein R; Kates RE; Kreipe HH; Harbeck N
JAMA Oncol; 2023 Jul; 9(7):946-954. PubMed ID: 37166817
[TBL] [Abstract][Full Text] [Related]
18. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
Llombart-Cussac A; Cortés J; Paré L; Galván P; Bermejo B; Martínez N; Vidal M; Pernas S; López R; Muñoz M; Nuciforo P; Morales S; Oliveira M; de la Peña L; Peláez A; Prat A
Lancet Oncol; 2017 Apr; 18(4):545-554. PubMed ID: 28238593
[TBL] [Abstract][Full Text] [Related]
19. Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.
Nuciforo P; Townend J; Piccart MJ; Fielding S; Gkolfi P; El-Abed S; de Azambuja E; Werutsky G; Bliss J; Moebus V; Colleoni M; Aspitia AM; Gomez H; Gombos A; Coccia-Portugal MA; Tseng LM; Kunz G; Lerzo G; Sohn J; Semiglazov V; Saura C; Kroep J; Ferro A; Cameron D; Gelber R; Huober J; Di Cosimo S
Eur J Cancer; 2023 Mar; 181():92-101. PubMed ID: 36641898
[TBL] [Abstract][Full Text] [Related]
20. Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial.
Di Cosimo S; Porcu L; Agbor-Tarh D; Cinieri S; Franzoi MA; De Santis MC; Saura C; Huober J; Fumagalli D; Izquierdo M; Piccart M; Daidone MG; de Azambuja E
Breast Cancer Res; 2020 Oct; 22(1):115. PubMed ID: 33109233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
